We do not currently track a confirmed FDA catalyst for Olema Pharmaceuticals, Inc.. Any decision listed below was inferred from share-price behaviour and has not been checked against a filing, so there is nothing we have verified to show here yet.
This page aggregates OLMA's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Computed from this stock's own daily closing prices, on the same T-120 basis as the run-up study: the baseline is the close 120 trading sessions before the eve of the decision. These are measurements of what already happened, not predictions.
| Decision | Outcome | T-120 to eve | T-120 to peak |
|---|---|---|---|
| 2023-12-05 | APPROVAL | +65.4% | +85.9% |
Olema Pharmaceuticals, Inc. has no dated FDA catalyst on our calendar right now. That means no scheduled decision or readout date has been published in a source we can point to, not that none exists. We would rather say that than estimate one.
We have no measured history for OLMA itself. Across the whole study of 1,835 FDA decisions, the median stock rose 17.8% at its best point in the 120 trading days before the decision, but was only 2.0% higher the day before it. Most of the move happened before the answer arrived and was largely given back.
FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.